Compare BridgeBio Pharma Inc (BBIO) vs EPAM Systems Inc (EPAM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs EPAM Systems Inc — how do they compare? BridgeBio Pharma Inc trades at $84.09 (market cap $16.46B), while EPAM Systems Inc trades at $85 (market cap $4.41B). The key difference: BridgeBio Pharma Inc is far larger — about 3.7× EPAM Systems Inc's market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, EPAM Systems Inc nearer its low. Which is the better fit depends on your goals.
| BBIO | EPAM | |
|---|---|---|
Market Cap | $16.46B | $4.41B |
Sector | Health | Technology |
52-Week High | $90.17 | $221.40 |
52-Week Low | $44.81 | $76.04 |
Enterprise Value | $18.02B | $3.67B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
EPAM trades at $86.38, up 2.97% on the day, with a bearish technical signal from moving averages but neutral oscillators. The stock shows attractive valuation with a P/E of 12.41 and P/S of 0.86, supported by consistent earnings beats in recent quarters. Revenue grew to $5.46B in 2025, though net income margin dipped to 6.96%. Recent news highlights EPAM's AI partnerships and upcoming Q2 earnings, with analyst sentiment strongly bullish.
The outlook for EPAM is positive given its low valuation multiples and strong analyst consensus, with a price target of $128.55 implying significant upside. Risks include competitive pressures in IT services and potential margin compression, but the company's focus on AI transformation and solid cash flow generation provide a foundation for growth. Investors should weigh the high institutional confidence against macroeconomic headwinds affecting the tech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About EPAM Systems Inc
EPAM Systems Inc provides software product development and digital platform engineering services to clients located around the world. The company services include Software Product Development, Custom Application Development, Application Testing, Enterprise Application Platforms, Application Maintenance, and Support and Infrastructure Management. The company focuses on innovative and scalable software solutions. The company uses industry standard and custom developed technology, tools, and platforms to deliver results to handle business challenges. The company primarily offers its solutions in the following industries: financial services, travel and consumer, software and hi-tech, life sciences and healthcare. The majority of revenue is generated from North American clients.
Read more on EPAM →
